ABIVAX SA

Abivax SA explores new acquisitions to boost its anti‑viral pipeline, sparking investor interest and potential stock gains.

Abivax’s $920 million capital raise lifts shares 7.7 % as it funds Obefazimod commercialization and expands its antiviral pipeline, sparking investor optimism.

Abivax SA’s €6.84 billion valuation surges after positive Phase‑III results for obefazimod (ABTECT), proving efficacy and safety for refractory ulcerative colitis and opening a new, lucrative UC market opportunity.

Abivax SA leads biotech with Phase II HIV cure trial ABX 464 and hepatitis B vaccine ABX 203, driving global infectious‑disease solutions and investor growth.

Abivax SA’s rising market sentiment stems from its growing anti‑viral pipeline and strategic collaborations, positioning it as a key player in global infectious disease therapeutics.

Abivax denies AstraZeneca takeover rumors, focusing on its pipeline of HIV, hepatitis B, and other infectious disease therapies.

Abivax’s obefazimod shows early anti‑fibrotic and symptomatic benefits in Crohn’s, with strong safety and regulatory progress highlighted at ECCO 2026.

Abivax SA’s advancing HIV, hepatitis B and other antiviral pipeline, coupled with takeover speculation, is driving investor optimism and share‑price momentum.

Abivax SA, a Paris‑based biotech, is pushing anti‑viral therapy and vaccine development, with key Phase II candidates like ABX 464 for HIV and ABX 203 for hepatitis B, while navigating volatile market trends.

Abivax SA